Can montelukast sodium be an alternative treatment in the treatment of interstitial cystitis?

Basit Öğe Kaydı
dc.contributor.authorGunizi, O. C.
dc.contributor.authorKol, A.
dc.contributor.authorGunizi, H.
dc.date.accessioned2026-01-24T12:26:39Z
dc.date.available2026-01-24T12:26:39Z
dc.date.issued2023
dc.departmentAlanya Alaaddin Keykubat Üniversitesi
dc.description.abstractBackground: The leukotriene D4 receptors have been detected in human bladder detrusor myocytes, and they can play the role of interstitial cystitis etiology. Aim: Our study aims to explain the role of mast cells histologically and immunohistochemically in the pathogenesis and the effectiveness of montelukast that leukotriene D4 receptor antagonist in the treatment of interstitial cystitis. Subjects and Methods: Twenty-four Wistar albino adult female rats were used. Group 1 (n = 8): control (sham) group, Group 2 (n = 8): interstitial cystitis group, and Group 3 (n = 8): treatment group. Groups 2 and 3 rats were administered 75 mg/kg cyclophosphamide four times every three days intraperitoneally. The rats in the treatment group were started on montelukast sodium as 10 mg/kg, 1 x 1/ day per orally after the last administration of cyclophosphamide and were given for 14 days. Mast cells in the bladder tissues were examined histologically, and the presence of IL-6, 8, VEGF, and TNF alpha was examined immunohistochemically. Results: Thin transitional epithelium, loose connective tissue, weak smooth muscle bundles, and signs of chronic inflammation were observed in the interstitial cystitis group. Regenerated transitional epithelium, intact basement membrane, compact lamina propia, thick smooth muscle bundles, and rare inflammatory cells were observed after the treatment with the montelukast. Mast cells were decreased in bladder tissue after treatment. IL-6, IL-8, VEGF, and TNF alpha levels were significantly decreased after treatment. Conclusions: We found that inflammatory mediators were significantly reduced after treatment with montelukast in the interstitial cystitis group. Montelukast can be used as an effective drug in the treatment of interstitial cystitis.
dc.identifier.doi10.4103/njcp.njcp_385_22
dc.identifier.endpage403
dc.identifier.issn1119-3077
dc.identifier.issn2229-7731
dc.identifier.issue4
dc.identifier.pmid37203102
dc.identifier.scopus2-s2.0-85159759867
dc.identifier.scopusqualityQ2
dc.identifier.startpage397
dc.identifier.urihttps://doi.org/10.4103/njcp.njcp_385_22
dc.identifier.urihttps://hdl.handle.net/20.500.12868/4842
dc.identifier.volume26
dc.identifier.wosWOS:001007490600005
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherWolters Kluwer Medknow Publications
dc.relation.ispartofNigerian Journal of Clinical Practice
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WoS_20260121
dc.subjectChronic pelvic pain
dc.subjectInterstitial cystitis
dc.subjectLeukotriene D4
dc.subjectMontelukast sodium
dc.titleCan montelukast sodium be an alternative treatment in the treatment of interstitial cystitis?
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu